New 3D Heart-Mapping tool could sharpen AFib ablation
NCT ID NCT06895187
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new device called the VERAFEYE System, which creates a 3D model of the heart to guide doctors during catheter ablation for paroxysmal atrial fibrillation (a type of irregular heartbeat). About 100 adults who are already scheduled for ablation will have the procedure guided by this system. The main goal is to see if doctors can successfully complete the ablation using the VERAFEYE's 3D map.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VERAFEYE System (imaging and navigation device)
What this could lead to
If successful, this could make catheter ablation for atrial fibrillation more precise and effective, potentially reducing the need for repeat procedures.
What could go wrong
This is an early-stage, non-randomized study with only 100 participants. The device may not improve outcomes over standard methods, and risks of ablation (like bleeding or heart damage) still apply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••